Literature DB >> 16611779

Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not.

J L Boxerman1, K M Schmainda, R M Weisskoff.   

Abstract

BACKGROUND AND
PURPOSE: Relative cerebral blood volume (rCBV) estimates for high-grade gliomas computed with dynamic susceptibility contrast MR imaging are artificially lowered by contrast extravasation through a disrupted blood-brain barrier. We hypothesized that rCBV corrected for agent leakage would correlate significantly with histopathologic tumor grade, whereas uncorrected rCBV would not.
METHODS: We performed dynamic T2*-weighted perfusion MR imaging on 43 patients with a cerebral glioma after prebolus gadolinium diethylene triamine penta-acetic acid administration to diminish competing extravasation-induced T1 effects. The rCBV was computed from non-necrotic enhancing tumor regions by integrating the relaxivity-time data, with and without contrast extravasation correction by using a linear fitting algorithm, and was normalized to contralateral brain. We determined the statistical correlation between corrected and uncorrected normalized rCBV and histopathologic tumor grade with the Spearman rank correlation test.
RESULTS: Eleven, 9, and 23 patients had WHO grades II, III, and IV glioma, respectively. Mean uncorrected normalized rCBVs were 1.53, 2.51, and 2.14 (grade II, III, and IV). Corrected normalized rCBVs were 1.52, 2.84, and 3.96. Mean absolute discrepancies between uncorrected and corrected rCBVs were 2% (0%-15%), 16% (0%-106%), and 74% (0%-411%). The correlation between corrected rCBV and tumor grade was significant (0.60; P < .0001), whereas it was not for uncorrected rCBV (0.15; P = .35).
CONCLUSION: For gliomas, rCBV estimation that correlates significantly with WHO tumor grade necessitates contrast extravasation correction. Without correction, artificially lowered rCBV may be construed erroneously to reflect lower tumor grade.

Entities:  

Mesh:

Year:  2006        PMID: 16611779      PMCID: PMC8134002     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  47 in total

1.  Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging.

Authors:  Marius Hartmann; Sabine Heiland; Inga Harting; Volker M Tronnier; Clemens Sommer; Roman Ludwig; Klaus Sartor
Journal:  Neurosci Lett       Date:  2003-02-27       Impact factor: 3.046

2.  Structural and functional characteristics of the microcirculation in neoplasms.

Authors:  J M Papadimitrou; A E Woods
Journal:  J Pathol       Date:  1975-06       Impact factor: 7.996

3.  Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects.

Authors:  A Villringer; B R Rosen; J W Belliveau; J L Ackerman; R B Lauffer; R B Buxton; Y S Chao; V J Wedeen; T J Brady
Journal:  Magn Reson Med       Date:  1988-02       Impact factor: 4.668

4.  Pitfalls in MR measurement of tissue blood flow with intravascular tracers: which mean transit time?

Authors:  R M Weisskoff; D Chesler; J L Boxerman; B R Rosen
Journal:  Magn Reson Med       Date:  1993-04       Impact factor: 4.668

5.  MR contrast due to intravascular magnetic susceptibility perturbations.

Authors:  J L Boxerman; L M Hamberg; B R Rosen; R M Weisskoff
Journal:  Magn Reson Med       Date:  1995-10       Impact factor: 4.668

6.  Three-dimensional observations on microvascular growth in rat glioma using a vascular casting method.

Authors:  A Zama; M Tamura; H K Inoue
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

7.  Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients.

Authors:  K M Donahue; H G Krouwer; S D Rand; A P Pathak; C S Marszalkowski; S C Censky; R W Prost
Journal:  Magn Reson Med       Date:  2000-06       Impact factor: 4.668

8.  Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications.

Authors:  P C Burger; F S Vogel; S B Green; T A Strike
Journal:  Cancer       Date:  1985-09-01       Impact factor: 6.860

9.  Dynamic contrast-enhanced MRI: differentiating melanoma and renal carcinoma metastases from high-grade astrocytomas and other metastases.

Authors:  S Kremer; S Grand; F Berger; D Hoffmann; B Pasquier; C Rémy; A L Benabid; J F Le Bas
Journal:  Neuroradiology       Date:  2002-12-07       Impact factor: 2.804

10.  Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI.

Authors:  Glyn Johnson; Stephan G Wetzel; Soonmee Cha; James Babb; Paul S Tofts
Journal:  Magn Reson Med       Date:  2004-05       Impact factor: 4.668

View more
  304 in total

1.  Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery.

Authors:  Stella Blasel; Kea Franz; Hanns Ackermann; Stefan Weidauer; Friedhelm Zanella; Elke Hattingen
Journal:  J Neurooncol       Date:  2010-10-07       Impact factor: 4.130

2.  New similarity search based glioma grading.

Authors:  Katrin Haegler; Martin Wiesmann; Christian Böhm; Jessica Freiherr; Oliver Schnell; Hartmut Brückmann; Jörg-Christian Tonn; Jennifer Linn
Journal:  Neuroradiology       Date:  2011-12-14       Impact factor: 2.804

3.  Perfusion magnetic resonance imaging in pediatric brain tumors.

Authors:  F Dallery; R Bouzerar; D Michel; C Attencourt; V Promelle; J Peltier; J M Constans; O Balédent; C Gondry-Jouet
Journal:  Neuroradiology       Date:  2017-08-31       Impact factor: 2.804

4.  Effects of perfusion on diffusion changes in human brain tumors.

Authors:  Alexander D Cohen; Peter S LaViolette; Melissa Prah; Jennifer Connelly; Mark G Malkin; Scott D Rand; Wade M Mueller; Kathleen M Schmainda
Journal:  J Magn Reson Imaging       Date:  2013-02-06       Impact factor: 4.813

5.  Slice accelerated gradient-echo spin-echo dynamic susceptibility contrast imaging with blipped CAIPI for increased slice coverage.

Authors:  Cornelius Eichner; Kourosh Jafari-Khouzani; Stephen Cauley; Himanshu Bhat; Pavlina Polaskova; Ovidiu C Andronesi; Otto Rapalino; Robert Turner; Lawrence L Wald; Steven Stufflebeam; Kawin Setsompop
Journal:  Magn Reson Med       Date:  2013-10-28       Impact factor: 4.668

6.  High-resolution longitudinal assessment of flow and permeability in mouse glioma vasculature: Sequential small molecule and SPIO dynamic contrast agent MRI.

Authors:  M M Pike; C N Stoops; C P Langford; N S Akella; L B Nabors; G Y Gillespie
Journal:  Magn Reson Med       Date:  2009-03       Impact factor: 4.668

7.  Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

Authors:  Peter S LaViolette; Alex D Cohen; Melissa A Prah; Scott D Rand; Jennifer Connelly; Mark G Malkin; Wade M Mueller; Kathleen M Schmainda
Journal:  Neuro Oncol       Date:  2013-02-03       Impact factor: 12.300

8.  Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.

Authors:  Asim K Bag; Phillip C Cezayirli; Jake J Davenport; Santhosh Gaddikeri; Hassan M Fathallah-Shaykh; Alan Cantor; Xiaosi S Han; Louis B Nabors
Journal:  J Neurooncol       Date:  2014-08-07       Impact factor: 4.130

9.  Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.

Authors:  Andrea Romano; Luca Pasquini; Alberto Di Napoli; Francesca Tavanti; Alessandro Boellis; Maria Camilla Rossi Espagnet; Giuseppe Minniti; Alessandro Bozzao
Journal:  J Neurooncol       Date:  2018-05-02       Impact factor: 4.130

10.  Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.

Authors:  Jelena Lazovic; Horacio Soto; David Piccioni; Jerry R Lou; Sichen Li; Leili Mirsadraei; William Yong; Robert Prins; Linda M Liau; Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Whitney B Pope
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.